186 related articles for article (PubMed ID: 11475010)
1. Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum.
Naudon L; Leroux-Nicollet I; Boulay D; Costentin J
J Neural Transm (Vienna); 2001; 108(4):431-44. PubMed ID: 11475010
[TBL] [Abstract][Full Text] [Related]
2. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum.
Kanthasamy A; Sprague JE; Shotwell JR; Nichols DE
Neuroscience; 2002; 114(4):917-24. PubMed ID: 12379247
[TBL] [Abstract][Full Text] [Related]
3. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
4. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
[TBL] [Abstract][Full Text] [Related]
5. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
6. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.
Frey K; Kilbourn M; Robinson T
Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.
Ekue A; Boulanger JF; Morissette M; Di Paolo T
J Neuroendocrinol; 2002 Sep; 14(9):731-6. PubMed ID: 12213134
[TBL] [Abstract][Full Text] [Related]
8. Consequences of an intrastriatal injection of kainic acid on the dopaminergic neuronal and vesicular uptake systems.
Naudon L; Leroux-Nicollet I; Costentin J
Brain Res; 1992 Oct; 593(1):32-8. PubMed ID: 1360863
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the subregional distributions of the monoamine vesicular transporter and dopamine uptake complex in the rat striatum and changes during aging.
Leroux-Nicollet I; Costentin J
J Neural Transm Gen Sect; 1994; 97(2):93-106. PubMed ID: 7873127
[TBL] [Abstract][Full Text] [Related]
10. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study.
Augood SJ; Hollingsworth Z; Albers DS; Yang L; Leung JC; Muller B; Klein C; Breakefield XO; Standaert DG
Neurology; 2002 Aug; 59(3):445-8. PubMed ID: 12177384
[TBL] [Abstract][Full Text] [Related]
11. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
Vilpoux C; Leroux-Nicollet I; Naudon L; Raisman-Vozari R; Costentin J
Neuropharmacology; 2000 Apr; 39(6):1075-82. PubMed ID: 10727718
[TBL] [Abstract][Full Text] [Related]
12. Dopamine transmission in DYT1 dystonia.
Augood SJ; Hollingsworth Z; Albers DS; Yang L; Leung J; Breakefield XO; Standaert DG
Adv Neurol; 2004; 94():53-60. PubMed ID: 14509654
[No Abstract] [Full Text] [Related]
13. Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood.
Moll GH; Mehnert C; Wicker M; Bock N; Rothenberger A; Rüther E; Huether G
Brain Res Dev Brain Res; 2000 Feb; 119(2):251-7. PubMed ID: 10675775
[TBL] [Abstract][Full Text] [Related]
14. Methamphetamine rapidly decreases vesicular dopamine uptake.
Brown JM; Hanson GR; Fleckenstein AE
J Neurochem; 2000 May; 74(5):2221-3. PubMed ID: 10800970
[TBL] [Abstract][Full Text] [Related]
15. Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat.
Barc S; Page G; Barrier L; Garreau L; Guilloteau D; Fauconneau B; Chalon S
J Neurochem; 2002 Feb; 80(3):365-74. PubMed ID: 11905985
[TBL] [Abstract][Full Text] [Related]
16. In vivo measures of dopaminergic radioligands in the rat brain: equilibrium infusion studies.
Kilbourn MR; Sherman PS; Kuszpit K
Synapse; 2002 Mar; 43(3):188-94. PubMed ID: 11793424
[TBL] [Abstract][Full Text] [Related]
17. Recovery of dopamine neuronal transporter but lack of change of its mRNA in substantia nigra after inactivation by a new irreversible inhibitor characterized in vitro and ex vivo in the rat.
Régo JC; Syringas M; Leblond B; Costentin J; Bonnet JJ
Br J Pharmacol; 1999 Sep; 128(1):51-60. PubMed ID: 10498834
[TBL] [Abstract][Full Text] [Related]
18. Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition.
Wayment HK; Schenk JO; Sorg BA
J Neurosci; 2001 Jan; 21(1):35-44. PubMed ID: 11150317
[TBL] [Abstract][Full Text] [Related]
19. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones.
Rehavi M; Goldin M; Roz N; Weizman A
Brain Res Mol Brain Res; 1998 Jun; 57(1):31-7. PubMed ID: 9630494
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain.
Kilbourn MR; Kemmerer ES; Desmond TJ; Sherman PS; Frey KA
Exp Neurol; 2004 Aug; 188(2):387-90. PubMed ID: 15246838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
